BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase III Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation

Brief Summary

Type:
Breast Cancer

Study Type:
Prevention

Phase:
III

ClinicalTrials.gov Identifier:
NCT04711109

Study #:
STUDY00148737

Start Date:
Aug 29, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04711109

View Complete Trial Details & Eligibility at ClinicalTrials.gov